This is a summary of the European public assessment report (EPAR) for Olazax Disperzi. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Olazax Disperzi.
Therapeutic Indication
### Therapeutic indication **Adults** Olanzapine is indicated for the treatment of schizophrenia. Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response. Olanzapine is indicated for the treatment of moderate to severe manic episode. In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder.
Therapeutic Area (MeSH)
N/AATC Code
N05AH03
ATC Item
olanzapine
Pharmacotherapeutic Group
Psycholeptics
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| olanzapine | N/A | 奥氮平 |
EMA Name
Olazax Disperzi
Medicine Name
Olazax Disperzi
Aliases
N/ANo risk management plan link.
